Front Row Advisors’s Biogen BIIB Stock Holding History

Front Row Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30	Closed	-$8K	–	941
2021 Q3	$8K	Hold	30	–	–	﹤0.01%	613
2021 Q2	$10K	Hold	30	–	–	﹤0.01%	558
2021 Q1	$8K	Hold	30	–	–	﹤0.01%	592
2020 Q4	$7K	Hold	30	–	–	﹤0.01%	596
2020 Q3	$7K	Sell	30 -22	-42%	-$6.14K	﹤0.01%	584
2020 Q2	$14K	Sell	52 -94	-64%	-$28.3K	0.01%	397
2020 Q1	$43K	Sell	146 -12	-8%	-$3.64K	0.03%	233
2019 Q4	$47K	Buy	158 +108	+216%	+$30K	0.03%	212
2019 Q3	$12K	Sell	50 -8	-14%	-$1.86K	0.01%	403
2019 Q2	$14K	Buy	58 +9	+18%	+$2.08K	0.01%	371
2019 Q1	$12K	Sell	49 -3,015	-98%	-$949K	0.01%	404
2018 Q4	$922K	Sell	3,064 -45	-1%	-$14.4K	0.8%	42
2018 Q3	$939K	Buy	3,109 +55	+2%	+$18.9K	0.66%	48
2018 Q2	$1.17M	Buy	3,054 +199	+7%	+$55.9K	0.75%	40
2018 Q1	$782K	Buy	2,855 +235	+9%	+$72.9K	0.55%	55
2017 Q4	$835K	Buy	+2,620	New	+$841K	0.66%	44

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Front Row Advisors's BIIB Position: Q4 2021 in Review

Front Row Advisors sold out of Biogen (BIIB) in Q4 2021, closing a stake of 30 shares — an estimated $8K sold.

Front Row Advisors first reported a position in BIIB in Q4 2017 and held it in 16 quarters. The position peaked at $1.17M in Q2 2018. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Front Row Advisors reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Front Row Advisors sold 30 Biogen shares in Q4 2021, an estimated $8K.
Front Row Advisors first reported a position in Biogen in Q4 2017 and held it in 16 quarters.
Front Row Advisors's Biogen position peaked at $1.17M in Q2 2018.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Front Row Advisors's 13F filing for Q4 2021, filed 9 Mar 2022.